{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:18:28Z","timestamp":1785460708641,"version":"3.56.0"},"publisher-location":"New York, NY","reference-count":212,"publisher":"Springer US","isbn-type":[{"value":"9781071637692","type":"print"},{"value":"9781071637708","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3770-8_3","type":"book-chapter","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:45:38Z","timestamp":1717062338000},"page":"51-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Negative-Strand RNA Virus-Vectored Vaccines"],"prefix":"10.1007","author":[{"given":"Magdalena","family":"Murr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mettenleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s00705-021-05143-6","volume":"166","author":"JH Kuhn","year":"2021","unstructured":"Kuhn JH, Adkins S, Agwanda BR et al (2021) 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Arch Virol 166:3513\u20133566","journal-title":"Arch Virol"},{"key":"3_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007873","volume":"15","author":"D Rubbenstroth","year":"2019","unstructured":"Rubbenstroth D, Schlottau K, Schwemmle M et al (2019) Human bornavirus research: back on track! PLoS Pathog 15:e1007873","journal-title":"PLoS Pathog"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/bs.aivir.2017.12.002","volume":"100","author":"J Emanuel","year":"2018","unstructured":"Emanuel J, Marzi A, Feldmann H (2018) Filoviruses: ecology, molecular biology, and evolution. Adv Virus Res 100:189\u2013221","journal-title":"Adv Virus Res"},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"1178122X1984992","DOI":"10.1177\/1178122X19849927","volume":"10","author":"S Languon","year":"2019","unstructured":"Languon S, Quaye O (2019) Filovirus disease outbreaks: a chronological overview. Virology (Auckl) 10:1178122X19849927","journal-title":"Virology (Auckl)"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.aivir.2017.12.003","volume":"100","author":"K Pfeffermann","year":"2018","unstructured":"Pfeffermann K, Dorr M, Zirkel F et al (2018) Morbillivirus pathogenesis and virus-host interactions. Adv Virus Res 100:75\u201398","journal-title":"Adv Virus Res"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/B978-0-444-53488-0.00032-8","volume":"123","author":"S Abdullah","year":"2014","unstructured":"Abdullah S, Tan CT (2014) Henipavirus encephalitis. Handb Clin Neurol 123:663\u2013670","journal-title":"Handb Clin Neurol"},{"key":"3_CR7","doi-asserted-by":"crossref","unstructured":"Gogoi P, Ganar K, Kumar S (2015) Avian paramyxovirus: a brief review. Transbound Emerg Dis","DOI":"10.1111\/tbed.12355"},{"key":"3_CR8","doi-asserted-by":"crossref","unstructured":"Su SB, Chang HL, Chen AK (2020) Current status of mumps virus infection: epidemiology, pathogenesis, and vaccine. Int J Environ Res Public Health 17","DOI":"10.3390\/ijerph17051686"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1055\/s-0036-1584798","volume":"37","author":"AR Branche","year":"2016","unstructured":"Branche AR, Falsey AR (2016) Parainfluenza virus infection. Semin Respir Crit Care Med 37:538\u2013554","journal-title":"Semin Respir Crit Care Med"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.rvsc.2006.03.009","volume":"82","author":"P Faisca","year":"2007","unstructured":"Faisca P, Desmecht D (2007) Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date. Res Vet Sci 82:115\u2013125","journal-title":"Res Vet Sci"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/CMR.00010-16","volume":"30","author":"C Griffiths","year":"2017","unstructured":"Griffiths C, Drews SJ, Marchant DJ (2017) Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev 30:277\u2013319","journal-title":"Clin Microbiol Rev"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","volume":"3","author":"AR Fooks","year":"2017","unstructured":"Fooks AR, Cliquet F, Finke S et al (2017) Rabies. Nat Rev Dis Primers 3:17091","journal-title":"Nat Rev Dis Primers"},{"key":"3_CR13","first-page":"880","volume-title":"Fields virology","author":"RA Lamb","year":"2013","unstructured":"Lamb RA (2013) Mononegavirales. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 880\u2013884"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1128\/jvi.67.8.4822-4830.1993","volume":"67","author":"P Calain","year":"1993","unstructured":"Calain P, Roux L (1993) The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67:4822\u20134830","journal-title":"J Virol"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1128\/JVI.72.2.891-899.1998","volume":"72","author":"D Kolakofsky","year":"1998","unstructured":"Kolakofsky D, Pelet T, Garcin D et al (1998) Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 72:891\u2013899","journal-title":"J Virol"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1128\/jvi.68.3.1382-1396.1994","volume":"68","author":"B Cubitt","year":"1994","unstructured":"Cubitt B, Oldstone C, De La Torre JC (1994) Sequence and genome organization of Borna disease virus. J Virol 68:1382\u20131396","journal-title":"J Virol"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/rmv.357","volume":"12","author":"B Gotoh","year":"2002","unstructured":"Gotoh B, Komatsu T, Takeuchi K et al (2002) Paramyxovirus strategies for evading the interferon response. Rev Med Virol 12:337\u2013357","journal-title":"Rev Med Virol"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1292\/jvms.16-0092","volume":"78","author":"N Ito","year":"2016","unstructured":"Ito N, Moseley GW, Sugiyama M (2016) The importance of immune evasion in the pathogenesis of rabies virus. J Vet Med Sci 78:1089\u20131098","journal-title":"J Vet Med Sci"},{"issue":"Suppl 2","key":"3_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1863-2378.2012.01454.x","volume":"59","author":"A Kuhl","year":"2012","unstructured":"Kuhl A, Pohlmann S (2012) How Ebola virus counters the interferon system. Zoonoses Public Health 59(Suppl 2):116\u2013131","journal-title":"Zoonoses Public Health"},{"key":"3_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1098612X12446638","volume":"14","author":"JJ Wensman","year":"2012","unstructured":"Wensman JJ, Jaderlund KH, Gustavsson MH et al (2012) Markers of Borna disease virus infection in cats with staggering disease. J Feline Med Surg 14:573\u2013582","journal-title":"J Feline Med Surg"},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fcimb.2020.00225","volume":"10","author":"EM Thornhill","year":"2020","unstructured":"Thornhill EM, Verhoeven D (2020) Respiratory syncytial virus\u2019s non-structural proteins: masters of interference. Front Cell Infect Microbiol 10:225","journal-title":"Front Cell Infect Microbiol"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1128\/jvi.68.8.5007-5012.1994","volume":"68","author":"PA Schneider","year":"1994","unstructured":"Schneider PA, Schneemann A, Lipkin WI (1994) RNA splicing in Borna disease virus, a nonsegmented, negative-strand RNA virus. J Virol 68:5007\u20135012","journal-title":"J Virol"},{"key":"3_CR23","doi-asserted-by":"publisher","first-page":"11486","DOI":"10.1073\/pnas.89.23.11486","volume":"89","author":"T Briese","year":"1992","unstructured":"Briese T, De La Torre JC, Lewis A et al (1992) Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A 89:11486\u201311489","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"e00175","DOI":"10.1128\/JVI.00175-20","volume":"94","author":"B Liang","year":"2020","unstructured":"Liang B (2020) Structures of the mononegavirales polymerases. J Virol 94:e00175\u2013e00120","journal-title":"J Virol"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1073\/pnas.73.2.442","volume":"73","author":"LA Ball","year":"1976","unstructured":"Ball LA, White CN (1976) Order of transcription of genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A 73:442\u2013446","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0092-8674(81)90143-4","volume":"23","author":"LE Iverson","year":"1981","unstructured":"Iverson LE, Rose JK (1981) Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23:477\u2013484","journal-title":"Cell"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.virol.2015.01.029","volume":"479-480","author":"CK Pfaller","year":"2015","unstructured":"Pfaller CK, Cattaneo R, Schnell MJ (2015) Reverse genetics of Mononegavirales: how they work, new vaccines, and new cancer therapeutics. Virology 479-480:331\u2013344","journal-title":"Virology"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1126\/science.1057269","volume":"291","author":"VE Volchkov","year":"2001","unstructured":"Volchkov VE, Volchkova VA, Muhlberger E et al (2001) Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291:1965\u20131969","journal-title":"Science"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"11563","DOI":"10.1073\/pnas.92.25.11563","volume":"92","author":"PL Collins","year":"1995","unstructured":"Collins PL, Hill MG, Camargo E et al (1995) Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5\u2032 proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 92:11563\u201311567","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1006\/viro.1995.1332","volume":"210","author":"LS Wyatt","year":"1995","unstructured":"Wyatt LS, Moss B, Rozenblatt S (1995) Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202\u2013205","journal-title":"Virology"},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0166-0934(96)02137-4","volume":"64","author":"H Schneider","year":"1997","unstructured":"Schneider H, Spielhofer P, Kaelin K et al (1997) Rescue of measles virus using a replication-deficient vaccinia-T7 vector. J Virol Methods 64:57\u201364","journal-title":"J Virol Methods"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s11033-008-9398-x","volume":"36","author":"Y Jiang","year":"2009","unstructured":"Jiang Y, Liu H, Liu P et al (2009) Plasmids driven minigenome rescue system for Newcastle disease virus V4 strain. Mol Biol Rep 36:1909\u20131914","journal-title":"Mol Biol Rep"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1128\/JVI.73.1.251-259.1999","volume":"73","author":"UJ Buchholz","year":"1999","unstructured":"Buchholz UJ, Finke S, Conzelmann KK (1999) Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73:251\u2013259","journal-title":"J Virol"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","volume":"14","author":"F Radecke","year":"1995","unstructured":"Radecke F, Spielhofer P, Schneider H et al (1995) Rescue of measles viruses from cloned DNA. EMBO J 14:5773\u20135784","journal-title":"EMBO J"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/350434a0","volume":"350","author":"AT Perrotta","year":"1991","unstructured":"Perrotta AT, Been MD (1991) A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350:434\u2013436","journal-title":"Nature"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejcb.2011.01.008","volume":"91","author":"A Ghanem","year":"2012","unstructured":"Ghanem A, Kern A, Conzelmann KK (2012) Significantly improved rescue of rabies virus from cDNA plasmids. Eur J Cell Biol 91:10\u201316","journal-title":"Eur J Cell Biol"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1128\/JVI.02389-05","volume":"80","author":"A Martin","year":"2006","unstructured":"Martin A, Staeheli P, Schneider U (2006) RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol 80:5708\u20135715","journal-title":"J Virol"},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00705-011-0932-0","volume":"156","author":"BY Li","year":"2011","unstructured":"Li BY, Li XR, Lan X et al (2011) Rescue of Newcastle disease virus from cloned cDNA using an RNA polymerase II promoter. Arch Virol 156:979\u2013986","journal-title":"Arch Virol"},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","volume":"13","author":"MJ Schnell","year":"1994","unstructured":"Schnell MJ, Mebatsion T, Conzelmann KK (1994) Infectious rabies viruses from cloned cDNA. EMBO J 13:4195\u20134203","journal-title":"EMBO J"},{"key":"3_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.virol.2017.06.003","volume":"509","author":"H Liu","year":"2017","unstructured":"Liu H, Albina E, Gil P et al (2017) Two-plasmid system to increase the rescue efficiency of paramyxoviruses by reverse genetics: the example of rescuing Newcastle Disease Virus. Virology 509:42\u201351","journal-title":"Virology"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.19182\/remvt.8771","volume":"42","author":"A Diallo","year":"1989","unstructured":"Diallo A, Taylor WP, Lefevre PC et al (1989) Attenuation of a strain of peste des petits ruminants virus: potential homologous live vaccine. Rev Elev Med Vet Pays Trop 42:311\u2013319","journal-title":"Rev Elev Med Vet Pays Trop"},{"key":"3_CR42","first-page":"3","volume":"329","author":"SL Katz","year":"2009","unstructured":"Katz SL (2009) John F. Enders and measles virus vaccine \u2013 a reminiscence. Curr Top Microbiol Immunol 329:3\u201311","journal-title":"Curr Top Microbiol Immunol"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"14141","DOI":"10.1128\/JVI.79.22.14141-14148.2005","volume":"79","author":"M Faber","year":"2005","unstructured":"Faber M, Faber ML, Papaneri A et al (2005) A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol 79:14141\u201314148","journal-title":"J Virol"},{"key":"3_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1073\/pnas.80.1.70","volume":"80","author":"B Dietzschold","year":"1983","unstructured":"Dietzschold B, Wunner WH, Wiktor TJ et al (1983) Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci U S A 80:70\u201374","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13365-015-0350-2","volume":"21","author":"S Zhu","year":"2015","unstructured":"Zhu S, Li H, Wang C et al (2015) Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development. J Neurovirol 21:335\u2013345","journal-title":"J Neurovirol"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.1128\/JVI.73.6.4705-4712.1999","volume":"73","author":"LA Ball","year":"1999","unstructured":"Ball LA, Pringle CR, Flanagan B et al (1999) Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73:4705\u20134712","journal-title":"J Virol"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.1128\/JVI.74.24.11626-11635.2000","volume":"74","author":"AA Haller","year":"2000","unstructured":"Haller AA, Miller T, Mitiku M et al (2000) Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74:11626\u201311635","journal-title":"J Virol"},{"key":"3_CR48","doi-asserted-by":"publisher","first-page":"15114","DOI":"10.1128\/JVI.79.24.15114-15122.2005","volume":"79","author":"QN Pham","year":"2005","unstructured":"Pham QN, Biacchesi S, Skiadopoulos MH et al (2005) Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol 79:15114\u201315122","journal-title":"J Virol"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1016\/j.vaccine.2005.10.047","volume":"24","author":"EJ Bartlett","year":"2006","unstructured":"Bartlett EJ, Amaro-Carambot E, Surman SR et al (2006) Introducing point and deletion mutations into the P\/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 24:2674\u20132684","journal-title":"Vaccine"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1128\/JVI.75.1.420-428.2001","volume":"75","author":"T Mebatsion","year":"2001","unstructured":"Mebatsion T, Verstegen S, De Vaan LT et al (2001) A recombinant newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos. J Virol 75:420\u2013428","journal-title":"J Virol"},{"key":"3_CR51","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1128\/jvi.70.4.2318-2323.1996","volume":"70","author":"MJ Schnell","year":"1996","unstructured":"Schnell MJ, Buonocore L, Whitt MA et al (1996) The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70:2318\u20132323","journal-title":"J Virol"},{"key":"3_CR52","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1128\/JVI.76.15.7642-7650.2002","volume":"76","author":"GW Wertz","year":"2002","unstructured":"Wertz GW, Moudy R, Ball LA (2002) Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J Virol 76:7642\u20137650","journal-title":"J Virol"},{"key":"3_CR53","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1099\/vir.0.18884-0","volume":"84","author":"H Zhao","year":"2003","unstructured":"Zhao H, Peeters BP (2003) Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol 84:781\u2013788","journal-title":"J Gen Virol"},{"key":"3_CR54","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1128\/JVI.74.15.6821-6831.2000","volume":"74","author":"AP Durbin","year":"2000","unstructured":"Durbin AP, Skiadopoulos MH, Mcauliffe JM et al (2000) Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol 74:6821\u20136831","journal-title":"J Virol"},{"key":"3_CR55","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1128\/JVI.02321-12","volume":"87","author":"Z Li","year":"2013","unstructured":"Li Z, Mooney AJ, Gabbard JD et al (2013) Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge. J Virol 87:354\u2013362","journal-title":"J Virol"},{"key":"3_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1099\/vir.0.027268-0","volume":"92","author":"K Ramp","year":"2011","unstructured":"Ramp K, Skiba M, Karger A et al (2011) Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression. J Gen Virol 92:355\u2013360","journal-title":"J Gen Virol"},{"key":"3_CR57","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.1128\/JVI.01815-15","volume":"89","author":"AH Malczyk","year":"2015","unstructured":"Malczyk AH, Kupke A, Prufer S et al (2015) a highly immunogenic and protective Middle East Respiratory Syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 89:11654\u201311667","journal-title":"J Virol"},{"key":"3_CR58","doi-asserted-by":"crossref","unstructured":"Murr M, Karger A, Steglich C et al (2020) Coexpression of soluble and membrane-bound avian influenza virus H5 by recombinant Newcastle disease virus leads to an increase in antigen levels. J Gen Virol","DOI":"10.1099\/jgv.0.001405"},{"key":"3_CR59","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1128\/JVI.76.7.3374-3381.2002","volume":"76","author":"M Faber","year":"2002","unstructured":"Faber M, Pulmanausahakul R, Hodawadekar SS et al (2002) Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol 76:3374\u20133381","journal-title":"J Virol"},{"key":"3_CR60","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0014-5793(99)00960-6","volume":"456","author":"Y Sakai","year":"1999","unstructured":"Sakai Y, Kiyotani K, Fukumura M et al (1999) Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication. FEBS Lett 456:221\u2013226","journal-title":"FEBS Lett"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"e01005","DOI":"10.1128\/mBio.01005-15","volume":"6","author":"SK Khattar","year":"2015","unstructured":"Khattar SK, Manoharan V, Bhattarai B et al (2015) Mucosal immunization with newcastle disease virus vector coexpressing HIV-1 Env and Gag proteins elicits potent serum, mucosal, and cellular immune responses that protect against Vaccinia virus Env and Gag challenges. mBio 6:e01005","journal-title":"mBio"},{"key":"3_CR62","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1099\/0022-1317-80-11-2987","volume":"80","author":"A R\u00f6mer-Oberd\u00f6rfer","year":"1999","unstructured":"R\u00f6mer-Oberd\u00f6rfer A, Mundt E, Mebatsion T et al (1999) Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol 80:2987\u20132995","journal-title":"J Gen Virol"},{"key":"3_CR63","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","volume":"73","author":"BP Peeters","year":"1999","unstructured":"Peeters BP, De Leeuw OS, Koch G et al (1999) Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73:5001\u20135009","journal-title":"J Virol"},{"key":"3_CR64","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1099\/0022-1317-82-7-1729","volume":"82","author":"Z Huang","year":"2001","unstructured":"Huang Z, Krishnamurthy S, Panda A et al (2001) High-level expression of a foreign gene from the most 3\u2032-proximal locus of a recombinant Newcastle disease virus. J Gen Virol 82:1729\u20131736","journal-title":"J Gen Virol"},{"key":"3_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0166-0934(02)00247-1","volume":"108","author":"I Engel-Herbert","year":"2003","unstructured":"Engel-Herbert I, Werner O, Teifke JP et al (2003) Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein. J Virol Methods 108:19\u201328","journal-title":"J Virol Methods"},{"key":"3_CR66","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/v12040451","volume":"12","author":"MB Bello","year":"2020","unstructured":"Bello MB, Yusoff K, Ideris A et al (2020) Exploring the prospects of engineered Newcastle disease virus in modern vaccinology. Viruses 12:451","journal-title":"Viruses"},{"key":"3_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072530","volume":"8","author":"C Steglich","year":"2013","unstructured":"Steglich C, Grund C, Ramp K et al (2013) Chimeric Newcastle disease virus protects chickens against avian influenza in the presence of maternally derived NDV immunity. PLoS One 8:e72530","journal-title":"PLoS One"},{"key":"3_CR68","doi-asserted-by":"publisher","first-page":"16854","DOI":"10.1038\/s41598-018-35337-z","volume":"8","author":"Y Cho","year":"2018","unstructured":"Cho Y, Lamichhane B, Nagy A et al (2018) Co-expression of the hemagglutinin and neuraminidase by heterologous Newcastle disease virus vectors protected chickens against H5 Clade 2.3.4.4 HPAI viruses. Sci Rep 8:16854","journal-title":"Sci Rep"},{"key":"3_CR69","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1637\/0005-2086-47.s3.1047","volume":"47","author":"DE Swayne","year":"2003","unstructured":"Swayne DE, Suarez DL, Schultz-Cherry S et al (2003) Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease. Avian Dis 47:1047\u20131050","journal-title":"Avian Dis"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"8203","DOI":"10.1073\/pnas.0602566103","volume":"103","author":"MS Park","year":"2006","unstructured":"Park MS, Steel J, Garcia-Sastre A et al (2006) Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A 103:8203\u20138208","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR71","doi-asserted-by":"publisher","first-page":"8197","DOI":"10.1073\/pnas.0602461103","volume":"103","author":"J Veits","year":"2006","unstructured":"Veits J, Wiesner D, Fuchs W et al (2006) Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc Natl Acad Sci U S A 103:8197\u20138202","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR72","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1128\/JVI.01514-06","volume":"81","author":"J Ge","year":"2007","unstructured":"Ge J, Deng G, Wen Z et al (2007) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 81:150\u2013158","journal-title":"J Virol"},{"key":"3_CR73","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.vaccine.2008.02.061","volume":"26","author":"A R\u00f6mer-Oberd\u00f6rfer","year":"2008","unstructured":"R\u00f6mer-Oberd\u00f6rfer A, Veits J, Helferich D et al (2008) Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus. Vaccine 26:2307\u20132313","journal-title":"Vaccine"},{"key":"3_CR74","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.vaccine.2008.01.016","volume":"26","author":"J Veits","year":"2008","unstructured":"Veits J, Romer-Oberdorfer A, Helferich D et al (2008) Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26:1688\u20131696","journal-title":"Vaccine"},{"key":"3_CR75","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1637\/8416-072308-Reg.1","volume":"53","author":"D Schr\u00f6er","year":"2009","unstructured":"Schr\u00f6er D, Veits J, Grund C et al (2009) Vaccination with Newcastle disease virus vectored vaccine protects chickens against highly pathogenic H7 avian influenza virus. Avian Dis 53:190\u2013197","journal-title":"Avian Dis"},{"key":"3_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006509","volume":"4","author":"B Nayak","year":"2009","unstructured":"Nayak B, Rout SN, Kumar S et al (2009) Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One 4:e6509","journal-title":"PLoS One"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1637\/10173-041012-ResNote.1","volume":"56","author":"A Lardinois","year":"2012","unstructured":"Lardinois A, Steensels M, Lambrecht B et al (2012) Potency of a recombinant NDV-H5 vaccine against various HPAI H5N1 virus challenges in SPF chickens. Avian Dis 56:928\u2013936","journal-title":"Avian Dis"},{"key":"3_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044447","volume":"7","author":"LA Cornelissen","year":"2012","unstructured":"Cornelissen LA, De Leeuw OS, Tacken MG et al (2012) Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice. PLoS One 7:e44447","journal-title":"PLoS One"},{"key":"3_CR79","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1637\/10148-040812-ResNote.1","volume":"56","author":"HL Ferreira","year":"2012","unstructured":"Ferreira HL, Pirlot JF, Reynard F et al (2012) Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian Dis 56:940\u2013948","journal-title":"Avian Dis"},{"key":"3_CR80","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1016\/j.vaccine.2013.06.074","volume":"31","author":"E Niqueux","year":"2013","unstructured":"Niqueux E, Guionie O, Amelot M et al (2013) Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus. Vaccine 31:4121\u20134128","journal-title":"Vaccine"},{"key":"3_CR81","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/03079457.2013.873111","volume":"43","author":"HL Ferreira","year":"2014","unstructured":"Ferreira HL, Rauw F, Pirlot JF et al (2014) Comparison of single 1-day-old chick vaccination using a Newcastle disease virus vector with a prime\/boost vaccination scheme against a highly pathogenic avian influenza H5N1 challenge. Avian Pathol 43:68\u201377","journal-title":"Avian Pathol"},{"key":"3_CR82","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1128\/JVI.00031-15","volume":"89","author":"Q Liu","year":"2015","unstructured":"Liu Q, Mena I, Ma J et al (2015) Newcastle disease virus-vectored H7 and H5 live vaccines protect chickens from challenge with H7N9 or H5N1 avian influenza viruses. J Virol 89:7401\u20137408","journal-title":"J Virol"},{"key":"3_CR83","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1016\/j.vaccine.2017.10.010","volume":"35","author":"Z Hu","year":"2017","unstructured":"Hu Z, Liu X, Jiao X et al (2017) Newcastle disease virus (NDV) recombinant expressing the hemagglutinin of H7N9 avian influenza virus protects chickens against NDV and highly pathogenic avian influenza A (H7N9) virus challenges. Vaccine 35:6585\u20136590","journal-title":"Vaccine"},{"key":"3_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41541-017-0034-4","volume":"2","author":"J Ma","year":"2017","unstructured":"Ma J, Lee J, Liu H et al (2017) Newcastle disease virus-based H5 influenza vaccine protects chickens from lethal challenge with a highly pathogenic H5N2 avian influenza virus. NPJ Vaccines 2:33","journal-title":"NPJ Vaccines"},{"key":"3_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.virol.2017.01.006","volume":"503","author":"SH Kim","year":"2017","unstructured":"Kim SH, Paldurai A, Samal SK (2017) A novel chimeric Newcastle disease virus vectored vaccine against highly pathogenic avian influenza virus. Virology 503:31\u201336","journal-title":"Virology"},{"key":"3_CR86","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1016\/j.vaccine.2017.06.055","volume":"35","author":"SH Kim","year":"2017","unstructured":"Kim SH, Samal SK (2017) Heterologous prime-boost immunization of Newcastle disease virus vectored vaccines protected broiler chickens against highly pathogenic avian influenza and Newcastle disease viruses. Vaccine 35:4133\u20134139","journal-title":"Vaccine"},{"key":"3_CR87","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1016\/j.vaccine.2018.09.015","volume":"36","author":"K Bertran","year":"2018","unstructured":"Bertran K, Lee DH, Criado MF et al (2018) Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens. Vaccine 36:6361\u20136372","journal-title":"Vaccine"},{"key":"3_CR88","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1016\/j.vaccine.2019.07.028","volume":"37","author":"I Roy Chowdhury","year":"2019","unstructured":"Roy Chowdhury I, Yeddula SGR, Pierce BG et al (2019) Newcastle disease virus vectors expressing consensus sequence of the H7 HA protein protect broiler chickens and turkeys against highly pathogenic H7N8 virus. Vaccine 37:4956\u20134962","journal-title":"Vaccine"},{"key":"3_CR89","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1637\/11965-090118-Reg.1","volume":"63","author":"L Shi","year":"2019","unstructured":"Shi L, Hu Z, Hu J et al (2019) Single immunization with Newcastle disease virus-vectored H7N9 vaccine confers a complete protection against challenge with highly pathogenic avian influenza H7N9 virus. Avian Dis 63:61\u201367","journal-title":"Avian Dis"},{"key":"3_CR90","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1637\/aviandiseases-D-20-00014","volume":"64","author":"M Murr","year":"2020","unstructured":"Murr M, Grund C, Breithaupt A et al (2020) Protection of chickens with maternal immunity againstavian influenza virus (AIV) by vaccination with a novel recombinant Newcastle disease virus vector. Avian Dis 64:427\u2013436","journal-title":"Avian Dis"},{"key":"3_CR91","doi-asserted-by":"publisher","first-page":"10054","DOI":"10.1128\/JVI.78.18.10054-10063.2004","volume":"78","author":"Z Huang","year":"2004","unstructured":"Huang Z, Elankumaran S, Yunus AS et al (2004) A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol 78:10054\u201310063","journal-title":"J Virol"},{"key":"3_CR92","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.vaccine.2014.01.020","volume":"32","author":"J Ge","year":"2014","unstructured":"Ge J, Wang X, Tian M et al (2014) Novel in-ovo chimeric recombinant Newcastle disease vaccine protects against both Newcastle disease and infectious bursal disease. Vaccine 32:1514\u20131521","journal-title":"Vaccine"},{"key":"3_CR93","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/vaccines5040031","volume":"5","author":"S Dey","year":"2017","unstructured":"Dey S, Chellappa MM, Pathak DC et al (2017) Newcastle disease virus vectored bivalent vaccine against virulent infectious bursal disease and Newcastle disease of chickens. Vaccines 5:31","journal-title":"Vaccines"},{"key":"3_CR94","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/vaccines9121483","volume":"9","author":"Q Qiao","year":"2021","unstructured":"Qiao Q, Song M, Song C et al (2021) Single-dose vaccination of recombinant chimeric Newcastle disease virus (NDV) LaSota vaccine strain expressing infectious bursal disease virus (IBDV) VP2 gene provides full protection against genotype VII NDV and IBDV challenge. Vaccines 9:1483","journal-title":"Vaccines"},{"key":"3_CR95","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.vaccine.2016.12.038","volume":"35","author":"Q Yu","year":"2017","unstructured":"Yu Q, Spatz S, Li Y et al (2017) Newcastle disease virus vectored infectious laryngotracheitis vaccines protect commercial broiler chickens in the presence of maternally derived antibodies. Vaccine 35:789\u2013795","journal-title":"Vaccine"},{"key":"3_CR96","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1016\/j.vaccine.2014.04.068","volume":"32","author":"M Kanabagatte Basavarajappa","year":"2014","unstructured":"Kanabagatte Basavarajappa M, Kumar S, Khattar SK et al (2014) A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens. Vaccine 32:3555\u20133563","journal-title":"Vaccine"},{"key":"3_CR97","doi-asserted-by":"publisher","first-page":"8397","DOI":"10.1128\/JVI.01321-14","volume":"88","author":"W Zhao","year":"2014","unstructured":"Zhao W, Spatz S, Zhang Z et al (2014) Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges. J Virol 88:8397\u20138406","journal-title":"J Virol"},{"key":"3_CR98","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1637\/10641-081613-Reg.1","volume":"58","author":"H Toro","year":"2014","unstructured":"Toro H, Zhao W, Breedlove C et al (2014) Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge. Avian Dis 58:83\u201389","journal-title":"Avian Dis"},{"key":"3_CR99","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.vaccine.2017.03.045","volume":"35","author":"R Zhao","year":"2017","unstructured":"Zhao R, Sun J, Qi T et al (2017) Recombinant Newcastle disease virus expressing the infectious bronchitis virus S1 gene protects chickens against Newcastle disease virus and infectious bronchitis virus challenge. Vaccine 35:2435\u20132442","journal-title":"Vaccine"},{"key":"3_CR100","doi-asserted-by":"publisher","first-page":"11951","DOI":"10.1038\/s41598-018-30356-2","volume":"8","author":"E Shirvani","year":"2018","unstructured":"Shirvani E, Paldurai A, Manoharan VK et al (2018) A recombinant Newcastle Disease Virus (NDV) expressing S protein of Infectious Bronchitis Virus (IBV) protects chickens against IBV and NDV. Sci Rep 8:11951","journal-title":"Sci Rep"},{"key":"3_CR101","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13567-019-0631-5","volume":"50","author":"HH Abozeid","year":"2019","unstructured":"Abozeid HH, Paldurai A, Varghese BP et al (2019) Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt. Vet Res 50:12","journal-title":"Vet Res"},{"key":"3_CR102","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/vaccines7040170","volume":"7","author":"L Tan","year":"2019","unstructured":"Tan L, Wen G, Qiu X et al (2019) A recombinant La Sota vaccine strain expressing multiple epitopes of infectious bronchitis virus (IBV) protects specific pathogen-free (SPF) chickens against IBV and NDV challenges. Vaccines 7:170","journal-title":"Vaccines"},{"key":"3_CR103","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/vaccines8040564","volume":"8","author":"L Tan","year":"2020","unstructured":"Tan L, Wen G, Yuan Y et al (2020) Development of a recombinant thermostable Newcastle disease virus (NDV) vaccine express infectious bronchitis virus (IBV) multiple epitopes for protecting against IBV and NDV challenges. Vaccines 8:564","journal-title":"Vaccines"},{"key":"3_CR104","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/v12070697","volume":"12","author":"E Shirvani","year":"2020","unstructured":"Shirvani E, Samal SK (2020) Comparative protective efficacies of novel avian paramyxovirus-vectored vaccines against virulent infectious bronchitis virus in chickens. Viruses 12:697","journal-title":"Viruses"},{"key":"3_CR105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1637\/0005-2086-64.1.53","volume":"64","author":"RA Zegpi","year":"2020","unstructured":"Zegpi RA, He L, Yu Q et al (2020) limited protection conferred by recombinant Newcastle disease virus expressing infectious bronchitis spike protein. Avian Dis 64:53\u201359","journal-title":"Avian Dis"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1637\/aviandiseases-D-21-00032","volume":"65","author":"Z Khalid","year":"2021","unstructured":"Khalid Z, He L, Yu Q et al (2021) Enhanced protection by recombinant Newcastle disease virus expressing infectious bronchitis virus spike ectodomain and chicken granulocyte-macrophage colony-stimulating factor. Avian Dis 65:364\u2013372","journal-title":"Avian Dis"},{"key":"3_CR107","doi-asserted-by":"publisher","first-page":"8624","DOI":"10.1016\/j.vaccine.2011.09.007","volume":"29","author":"H Hu","year":"2011","unstructured":"Hu H, Roth JP, Estevez CN et al (2011) Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroup C as a bivalent vaccine in turkeys. Vaccine 29:8624\u20138633","journal-title":"Vaccine"},{"key":"3_CR108","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.virusres.2015.04.006","volume":"203","author":"J Wang","year":"2015","unstructured":"Wang J, Cong Y, Yin R et al (2015) Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of Goose parvovirus as a bivalent vaccine in goslings. Virus Res 203:77\u201383","journal-title":"Virus Res"},{"key":"3_CR109","doi-asserted-by":"publisher","first-page":"36840","DOI":"10.1038\/srep36840","volume":"6","author":"M Olbert","year":"2016","unstructured":"Olbert M, R\u00f6mer-Oberd\u00f6rfer A, Herden C et al (2016) Viral vector vaccines expressing nucleoprotein and phosphoprotein genes of avian bornaviruses ameliorate homologous challenge infections in cockatiels and common canaries. Sci Rep 6:36840","journal-title":"Sci Rep"},{"key":"3_CR110","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.vaccine.2016.12.022","volume":"35","author":"S Runge","year":"2017","unstructured":"Runge S, Olbert M, Herden C et al (2017) Viral vector vaccines protect cockatiels from inflammatory lesions after heterologous parrot bornavirus 2 challenge infection. Vaccine 35:557\u2013563","journal-title":"Vaccine"},{"key":"3_CR111","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00705-008-0099-5","volume":"153","author":"M Subbiah","year":"2008","unstructured":"Subbiah M, Yan Y, Rockemann D et al (2008) Experimental infection of calves with Newcastle disease virus induces systemic and mucosal antibody responses. Arch Virol 153:1197\u20131200","journal-title":"Arch Virol"},{"key":"3_CR112","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1016\/j.vaccine.2010.02.051","volume":"28","author":"SK Khattar","year":"2010","unstructured":"Khattar SK, Collins PL, Samal SK (2010) Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 28:3159\u20133170","journal-title":"Vaccine"},{"key":"3_CR113","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1016\/j.vaccine.2010.04.048","volume":"28","author":"J Kortekaas","year":"2010","unstructured":"Kortekaas J, De Boer SM, Kant J et al (2010) Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 28:4394\u20134401","journal-title":"Vaccine"},{"key":"3_CR114","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.vaccine.2010.01.001","volume":"28","author":"J Kortekaas","year":"2010","unstructured":"Kortekaas J, Dekker A, De Boer SM et al (2010) Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 28:2271\u20132276","journal-title":"Vaccine"},{"key":"3_CR115","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4161\/bbug.2.1.13349","volume":"2","author":"MM Harmsen","year":"2011","unstructured":"Harmsen MM, Antonis AF, Moormann RJ et al (2011) Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety. Bioeng Bugs 2:58\u201362","journal-title":"Bioeng Bugs"},{"key":"3_CR116","doi-asserted-by":"publisher","first-page":"8241","DOI":"10.1128\/JVI.00519-11","volume":"85","author":"J Ge","year":"2011","unstructured":"Ge J, Wang X, Tao L et al (2011) Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J Virol 85:8241\u20138252","journal-title":"J Virol"},{"key":"3_CR117","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4142\/jvs.2017.18.S1.351","volume":"18","author":"GM Yu","year":"2017","unstructured":"Yu GM, Zu SL, Zhou WW et al (2017) Chimeric rabies glycoprotein with a transmembrane domain and cytoplasmic tail from Newcastle disease virus fusion protein incorporates into the Newcastle disease virion at reduced levels. J Vet Sci 18:351\u2013359","journal-title":"J Vet Sci"},{"key":"3_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2020.108890","volume":"251","author":"A Debnath","year":"2020","unstructured":"Debnath A, Pathak DC, D\u2019silva AL et al (2020) Newcastle disease virus vectored rabies vaccine induces strong humoral and cell mediated immune responses in mice. Vet Microbiol 251:108890","journal-title":"Vet Microbiol"},{"key":"3_CR119","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.virol.2012.06.001","volume":"432","author":"D Kong","year":"2012","unstructured":"Kong D, Wen Z, Su H et al (2012) Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology 432:327\u2013335","journal-title":"Virology"},{"key":"3_CR120","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.vaccine.2015.03.091","volume":"33","author":"J Ge","year":"2015","unstructured":"Ge J, Wang X, Tian M et al (2015) Recombinant Newcastle disease viral vector expressing hemagglutinin or fusion of canine distemper virus is safe and immunogenic in minks. Vaccine 33:2457\u20132462","journal-title":"Vaccine"},{"key":"3_CR121","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12985-016-0568-5","volume":"13","author":"J Wang","year":"2016","unstructured":"Wang J, Yang J, Ge J et al (2016) Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry. Virol J 13:109","journal-title":"Virol J"},{"key":"3_CR122","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12985-016-0481-y","volume":"13","author":"M Zhang","year":"2016","unstructured":"Zhang M, Ge J, Li X et al (2016) Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice. Virol J 13:31","journal-title":"Virol J"},{"key":"3_CR123","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12250-015-3692-2","volume":"31","author":"X Chen","year":"2016","unstructured":"Chen X, Yang J, Ji Y et al (2016) Recombinant Newcastle disease virus expressing African swine fever virus protein 72 is safe and immunogenic in mice. Virologica Sinica 31:150\u2013159","journal-title":"Virologica Sinica"},{"key":"3_CR124","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00705-016-3078-2","volume":"162","author":"M Zhang","year":"2017","unstructured":"Zhang M, Ge J, Wen Z et al (2017) Characterization of a recombinant Newcastle disease virus expressing the glycoprotein of bovine ephemeral fever virus. Arch Virol 162:359\u2013367","journal-title":"Arch Virol"},{"key":"3_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2019.108490","volume":"239","author":"H Zhang","year":"2019","unstructured":"Zhang H, Nan F, Li Z et al (2019) Construction and immunological evaluation of recombinant Newcastle disease virus vaccines expressing highly pathogenic porcine reproductive and respiratory syndrome virus GP3\/GP5 proteins in pigs. Vet Microbiol 239:108490","journal-title":"Vet Microbiol"},{"key":"3_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2021.109201","volume":"261","author":"FZ Fakri","year":"2021","unstructured":"Fakri FZ, Bamouh Z, Elmejdoub S et al (2021) Long term immunity against Peste Des Petits Ruminants mediated by a recombinant Newcastle disease virus vaccine. Vet Microbiol 261:109201","journal-title":"Vet Microbiol"},{"key":"3_CR127","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/vaccines8020205","volume":"8","author":"M Murr","year":"2020","unstructured":"Murr M, Hoffmann B, Grund C et al (2020) A novel recombinant Newcastle disease virus vectored DIVA vaccine against Peste des Petits ruminants in goats. Vaccines 8:205","journal-title":"Vaccines"},{"key":"3_CR128","doi-asserted-by":"publisher","first-page":"11868","DOI":"10.1128\/JVI.75.23.11868-11873.2001","volume":"75","author":"T Nakaya","year":"2001","unstructured":"Nakaya T, Cros J, Park MS et al (2001) Recombinant Newcastle disease virus as a vaccine vector. J Virol 75:11868\u201311873","journal-title":"J Virol"},{"key":"3_CR129","doi-asserted-by":"publisher","first-page":"13275","DOI":"10.1128\/JVI.79.21.13275-13284.2005","volume":"79","author":"A Bukreyev","year":"2005","unstructured":"Bukreyev A, Huang Z, Yang L et al (2005) Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 79:13275\u201313284","journal-title":"J Virol"},{"key":"3_CR130","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1128\/JVI.80.3.1130-1139.2006","volume":"80","author":"L Martinez-Sobrido","year":"2006","unstructured":"Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al (2006) Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 80:1130\u20131139","journal-title":"J Virol"},{"key":"3_CR131","doi-asserted-by":"publisher","first-page":"9788","DOI":"10.1073\/pnas.0703584104","volume":"104","author":"JM DiNapoli","year":"2007","unstructured":"DiNapoli JM, Kotelkin A, Yang L et al (2007) Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 104:9788\u20139793","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR132","doi-asserted-by":"crossref","unstructured":"DiNapoli JM, Yang L, Suguitan A Jr et al (2007) Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 81:11560\u201311568","DOI":"10.1128\/JVI.00713-07"},{"key":"3_CR133","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1128\/JVI.01946-09","volume":"84","author":"JM DiNapoli","year":"2010","unstructured":"DiNapoli JM, Nayak B, Yang L et al (2010) Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 84:1489\u20131503","journal-title":"J Virol"},{"key":"3_CR134","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.vaccine.2010.10.024","volume":"29","author":"JM DiNapoli","year":"2010","unstructured":"DiNapoli JM, Yang L, Samal SK et al (2010) Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 29:17\u201325","journal-title":"Vaccine"},{"key":"3_CR135","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1128\/JVI.05050-11","volume":"85","author":"SK Khattar","year":"2011","unstructured":"Khattar SK, Samal S, Devico AL et al (2011) Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol 85:10529\u201310541","journal-title":"J Virol"},{"key":"3_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078521","volume":"8","author":"SK Khattar","year":"2013","unstructured":"Khattar SK, Samal S, Labranche CC et al (2013) Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PLoS One 8:e78521","journal-title":"PLoS One"},{"key":"3_CR137","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4161\/21645515.2014.987006","volume":"11","author":"SK Khattar","year":"2015","unstructured":"Khattar SK, Palaniyandi S, Samal S et al (2015) Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. Hum Vaccin Immunother 11:504\u2013515","journal-title":"Hum Vaccin Immunother"},{"key":"3_CR138","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.virol.2015.06.003","volume":"484","author":"SH Kim","year":"2015","unstructured":"Kim SH, Chen S, Jiang X et al (2015) Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein. Virology 484:163\u2013169","journal-title":"Virology"},{"key":"3_CR139","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.1128\/JVI.01570-14","volume":"88","author":"SH Kim","year":"2014","unstructured":"Kim SH, Chen S, Jiang X et al (2014) Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J Virol 88:9718\u20139727","journal-title":"J Virol"},{"key":"3_CR140","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1038\/s41598-018-27433-x","volume":"8","author":"VK Manoharan","year":"2018","unstructured":"Manoharan VK, Khattar SK, Labranche CC et al (2018) Modified Newcastle disease virus as an improved vaccine vector against Simian immunodeficiency virus. Sci Rep 8:8952","journal-title":"Sci Rep"},{"key":"3_CR141","doi-asserted-by":"publisher","first-page":"e00976","DOI":"10.1128\/JVI.00976-18","volume":"92","author":"EG Viktorova","year":"2018","unstructured":"Viktorova EG, Khattar SK, Kouiavskaia D et al (2018) Newcastle disease virus-based vectored vaccine against poliomyelitis. J Virol 92:e00976\u2013e00918","journal-title":"J Virol"},{"key":"3_CR142","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1038\/s41598-019-42004-4","volume":"9","author":"A Yoshida","year":"2019","unstructured":"Yoshida A, Kim SH, Manoharan VK et al (2019) Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs. Sci Rep 9:5520","journal-title":"Sci Rep"},{"key":"3_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103132","volume":"62","author":"W Sun","year":"2020","unstructured":"Sun W, Leist SR, Mccroskery S et al (2020) Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine 62:103132","journal-title":"EBioMedicine"},{"key":"3_CR144","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1038\/s41467-021-26499-y","volume":"12","author":"W Sun","year":"2021","unstructured":"Sun W, Liu Y, Amanat F et al (2021) A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat Commun 12:6197","journal-title":"Nat Commun"},{"key":"3_CR145","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01908-21","volume":"12","author":"JH Lara-Puente","year":"2021","unstructured":"Lara-Puente JH, Carreno JM, Sun W et al (2021) Safety and immunogenicity of a Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX\/COVID-12-HEXAPRO (Patria), in Pigs. mBio 12:e0190821","journal-title":"mBio"},{"key":"3_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102941","volume":"24","author":"JG Park","year":"2021","unstructured":"Park JG, Oladunni FS, Rohaim MA et al (2021) Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2. iScience 24:102941","journal-title":"iScience"},{"key":"3_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103219","volume":"24","author":"BM Warner","year":"2021","unstructured":"Warner BM, Santry LA, Leacy A et al (2021) Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease. iScience 24:103219","journal-title":"iScience"},{"key":"3_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791764","volume":"12","author":"J Tcheou","year":"2021","unstructured":"Tcheou J, Raskin A, Singh G et al (2021) Safety and immunogenicity analysis of a newcastle disease virus (NDV-HXP-S) expressing the spike protein of SARS-CoV-2 in Sprague Dawley Rats. Front Immunol 12:791764","journal-title":"Front Immunol"},{"key":"3_CR149","doi-asserted-by":"publisher","first-page":"839","DOI":"10.20506\/rst.30.3.2081","volume":"30","author":"DE Swayne","year":"2011","unstructured":"Swayne DE, Pavade G, Hamilton K et al (2011) Assessment of national strategies for control of high-pathogenicity avian influenza and low-pathogenicity notifiable avian influenza in poultry, with emphasis on vaccines and vaccination. Rev Sci Tech 30:839\u2013870","journal-title":"Rev Sci Tech"},{"key":"3_CR150","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/fmb.12.4","volume":"7","author":"D Zamarin","year":"2012","unstructured":"Zamarin D, Palese P (2012) Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7:347\u2013367","journal-title":"Future Microbiol"},{"key":"3_CR151","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/cancers12123552","volume":"12","author":"B Burman","year":"2020","unstructured":"Burman B, Pesci G, Zamarin D (2020) Newcastle disease virus at the forefront of cancer immunotherapy. Cancers (Basel) 12:3552","journal-title":"Cancers (Basel)"},{"key":"3_CR152","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/biomedicines4030016","volume":"4","author":"V Schirrmacher","year":"2016","unstructured":"Schirrmacher V (2016) Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicines 4:16","journal-title":"Biomedicines"},{"key":"3_CR153","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1099\/0022-1317-80-1-101","volume":"80","author":"M Singh","year":"1999","unstructured":"Singh M, Billeter MA (1999) A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol 80:101\u2013106","journal-title":"J Gen Virol"},{"key":"3_CR154","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","volume":"73","author":"M Singh","year":"1999","unstructured":"Singh M, Cattaneo R, Billeter MA (1999) A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73:4823\u20134828","journal-title":"J Virol"},{"key":"3_CR155","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s11262-017-1486-3","volume":"53","author":"MD M\u00fchlebach","year":"2017","unstructured":"M\u00fchlebach MD (2017) Vaccine platform recombinant measles virus. Virus Genes 53:733\u2013740","journal-title":"Virus Genes"},{"key":"3_CR156","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","volume":"31","author":"S Brandler","year":"2013","unstructured":"Brandler S, Ruffie C, Combredet C et al (2013) A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31:3718\u20133725","journal-title":"Vaccine"},{"key":"3_CR157","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/infdis\/jiz202","volume":"220","author":"SL Rossi","year":"2019","unstructured":"Rossi SL, Comer JE, Wang E et al (2019) Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman primates. J Infect Dis 220:735\u2013742","journal-title":"J Infect Dis"},{"key":"3_CR158","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","volume":"15","author":"K Ramsauer","year":"2015","unstructured":"Ramsauer K, Schwameis M, Firbas C et al (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15:519\u2013527","journal-title":"Lancet Infect Dis"},{"key":"3_CR159","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","volume":"392","author":"EC Reisinger","year":"2019","unstructured":"Reisinger EC, Tschismarov R, Beubler E et al (2019) Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 392:2718\u20132727","journal-title":"Lancet"},{"key":"3_CR160","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cancers13030544","volume":"13","author":"CE Engeland","year":"2021","unstructured":"Engeland CE, Ungerechts G (2021) Measles virus as an oncolytic immunotherapy. Cancers (Basel) 13:544","journal-title":"Cancers (Basel)"},{"key":"3_CR161","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1014042221888","volume":"24","author":"JT Newman","year":"2002","unstructured":"Newman JT, Surman SR, Riggs JM et al (2002) Sequence analysis of the Washington\/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 24:77\u201392","journal-title":"Virus Genes"},{"key":"3_CR162","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/viro.2001.0864","volume":"284","author":"M Kawano","year":"2001","unstructured":"Kawano M, Kaito M, Kozuka Y et al (2001) Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology 284:99\u2013112","journal-title":"Virology"},{"key":"3_CR163","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1128\/jvi.71.6.4272-4277.1997","volume":"71","author":"MA Hoffman","year":"1997","unstructured":"Hoffman MA, Banerjee AK (1997) An infectious clone of human parainfluenza virus type 3. J Virol 71:4272\u20134277","journal-title":"J Virol"},{"key":"3_CR164","doi-asserted-by":"publisher","first-page":"8922","DOI":"10.1128\/JVI.74.19.8922-8929.2000","volume":"74","author":"AC Schmidt","year":"2000","unstructured":"Schmidt AC, Mcauliffe JM, Huang A et al (2000) Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74:8922\u20138929","journal-title":"J Virol"},{"key":"3_CR165","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1016\/j.vaccine.2011.12.022","volume":"30","author":"RA Karron","year":"2012","unstructured":"Karron RA, Thumar B, Schappell E et al (2012) Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 30:3975\u20133981","journal-title":"Vaccine"},{"key":"3_CR166","doi-asserted-by":"publisher","first-page":"10819","DOI":"10.1128\/JVI.77.20.10819-10828.2003","volume":"77","author":"RS Tang","year":"2003","unstructured":"Tang RS, Schickli JH, Macphail M et al (2003) Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3\u2032 proximal genome positions of bovine\/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 77:10819\u201310828","journal-title":"J Virol"},{"key":"3_CR167","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/INF.0b013e31823386f1","volume":"31","author":"DI Bernstein","year":"2012","unstructured":"Bernstein DI, Malkin E, Abughali N et al (2012) Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 31:109\u2013114","journal-title":"Pediatr Infect Dis J"},{"key":"3_CR168","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/INF.0b013e318199c3b1","volume":"28","author":"M Gomez","year":"2009","unstructured":"Gomez M, Mufson MA, Dubovsky F et al (2009) Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 28:655\u2013658","journal-title":"Pediatr Infect Dis J"},{"key":"3_CR169","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/j.vaccine.2013.04.006","volume":"31","author":"CF Yang","year":"2013","unstructured":"Yang CF, Wang CK, Malkin E et al (2013) Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine 31:2822\u20132827","journal-title":"Vaccine"},{"key":"3_CR170","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1128\/JVI.03481-13","volume":"88","author":"B Liang","year":"2014","unstructured":"Liang B, Munir S, Amaro-Carambot E et al (2014) Chimeric bovine\/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. J Virol 88:4237\u20134250","journal-title":"J Virol"},{"key":"3_CR171","doi-asserted-by":"publisher","first-page":"10498","DOI":"10.1128\/JVI.75.21.10498-10504.2001","volume":"75","author":"MH Skiadopoulos","year":"2001","unstructured":"Skiadopoulos MH, Surman SR, Riggs JM et al (2001) A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J Virol 75:10498\u201310504","journal-title":"J Virol"},{"key":"3_CR172","doi-asserted-by":"publisher","first-page":"e02469","DOI":"10.1128\/JVI.02469-16","volume":"91","author":"M Lingemann","year":"2017","unstructured":"Lingemann M, Liu X, Surman S et al (2017) Attenuated human parainfluenza virus type 1 expressing Ebola virus glycoprotein GP administered intranasally is immunogenic in African Green Monkeys. J Virol 91:e02469\u2013e02416","journal-title":"J Virol"},{"key":"3_CR173","doi-asserted-by":"publisher","first-page":"12901","DOI":"10.1038\/s41598-019-49579-y","volume":"9","author":"J Ohtsuka","year":"2019","unstructured":"Ohtsuka J, Fukumura M, Furuyama W et al (2019) A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector. Sci Rep 9:12901","journal-title":"Sci Rep"},{"key":"3_CR174","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.virol.2008.09.030","volume":"383","author":"A Bukreyev","year":"2009","unstructured":"Bukreyev A, Marzi A, Feldmann F et al (2009) Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 383:348\u2013361","journal-title":"Virology"},{"key":"3_CR175","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1965","volume":"28","author":"Z Chen","year":"2018","unstructured":"Chen Z (2018) Parainfluenza virus 5-vectored vaccines against human and animal infectious diseases. Rev Med Virol 28:e1965","journal-title":"Rev Med Virol"},{"key":"3_CR176","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1073\/pnas.0405965102","volume":"102","author":"U Schneider","year":"2005","unstructured":"Schneider U, Schwemmle M, Staeheli P (2005) Genome trimming: a unique strategy for replication control employed by Borna disease virus. Proc Natl Acad Sci U S A 102:3441\u20133446","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR177","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3389\/fmicb.2019.02485","volume":"10","author":"Y Yamamoto","year":"2019","unstructured":"Yamamoto Y, Tomonaga K, Honda T (2019) Development of an RNA virus-based episomal vector capable of switching transgene expression. Front Microbiol 10:2485","journal-title":"Front Microbiol"},{"key":"3_CR178","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.antiviral.2017.04.018","volume":"143","author":"T Tokunaga","year":"2017","unstructured":"Tokunaga T, Yamamoto Y, Sakai M et al (2017) Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses. Antiviral Res 143:237\u2013245","journal-title":"Antiviral Res"},{"key":"3_CR179","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coviro.2020.05.011","volume":"44","author":"Y Komatsu","year":"2020","unstructured":"Komatsu Y, Tomonaga K (2020) Reverse genetics approaches of Borna disease virus: applications in development of viral vectors and preventive vaccines. Curr Opin Virol 44:42\u201348","journal-title":"Curr Opin Virol"},{"key":"3_CR180","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/1348-0421.12505","volume":"61","author":"K Fujino","year":"2017","unstructured":"Fujino K, Yamamoto Y, Daito T et al (2017) Generation of a non-transmissive Borna disease virus vector lacking both matrix and glycoprotein genes. Microbiol Immunol 61:380\u2013386","journal-title":"Microbiol Immunol"},{"key":"3_CR181","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","volume":"92","author":"ND Lawson","year":"1995","unstructured":"Lawson ND, Stillman EA, Whitt MA et al (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92:4477\u20134481","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR182","doi-asserted-by":"publisher","first-page":"8388","DOI":"10.1073\/pnas.92.18.8388","volume":"92","author":"SP Whelan","year":"1995","unstructured":"Whelan SP, Ball LA, Barr JN et al (1995) Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A 92:8388\u20138392","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR183","doi-asserted-by":"publisher","first-page":"7310","DOI":"10.1073\/pnas.93.14.7310","volume":"93","author":"T Mebatsion","year":"1996","unstructured":"Mebatsion T, Schnell MJ, Cox JH et al (1996) Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci U S A 93:7310\u20137314","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR184","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.coviro.2020.09.003","volume":"44","author":"G Scher","year":"2020","unstructured":"Scher G, Schnell MJ (2020) Rhabdoviruses as vectors for vaccines and therapeutics. Curr Opin Virol 44:169\u2013182","journal-title":"Curr Opin Virol"},{"key":"3_CR185","doi-asserted-by":"publisher","first-page":"409","DOI":"10.20506\/rst.37.2.2811","volume":"37","author":"T M\u00fcller","year":"2018","unstructured":"M\u00fcller T, Freuling CM (2018) Rabies control in Europe: an overview of past, current and future strategies. Rev Sci Tech 37:409\u2013419","journal-title":"Rev Sci Tech"},{"key":"3_CR186","first-page":"178","volume":"125","author":"T M\u00fcller","year":"2012","unstructured":"M\u00fcller T, Batza HJ, Freuling CM et al (2012) Elimination of terrestrial rabies in Germany using oral vaccination of foxes. Berliner und Munchener tierarztliche Wochenschrift 125:178\u2013190","journal-title":"Berliner und Munchener tierarztliche Wochenschrift"},{"key":"3_CR187","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1016\/j.vaccine.2017.09.093","volume":"37","author":"CM Freuling","year":"2019","unstructured":"Freuling CM, Eggerbauer E, Finke S et al (2019) Efficacy of the oral rabies virus vaccine strain SPBN GASGAS in foxes and raccoon dogs. Vaccine 37:4750\u20134757","journal-title":"Vaccine"},{"key":"3_CR188","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","volume":"181","author":"EO Saphire","year":"2020","unstructured":"Saphire EO (2020) A vaccine against Ebola virus. Cell 181:6\u20136","journal-title":"Cell"},{"key":"3_CR189","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","volume":"78","author":"M Garbutt","year":"2004","unstructured":"Garbutt M, Liebscher R, Wahl-Jensen V et al (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78:5458\u20135465","journal-title":"J Virol"},{"key":"3_CR190","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones SM, Feldmann H, Stroher U et al (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786\u2013790","journal-title":"Nat Med"},{"key":"3_CR191","doi-asserted-by":"publisher","first-page":"E819","DOI":"10.1503\/cmaj.170074","volume":"189","author":"MS ElSherif","year":"2017","unstructured":"ElSherif MS, Brown C, Mackinnon-Cameron D et al (2017) Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ 189:E819\u2013E827","journal-title":"CMAJ"},{"key":"3_CR192","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/vim.2004.17.516","volume":"17","author":"GN Barber","year":"2004","unstructured":"Barber GN (2004) Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 17:516\u2013527","journal-title":"Viral Immunol"},{"key":"3_CR193","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1038\/sj.onc.1209042","volume":"24","author":"GN Barber","year":"2005","unstructured":"Barber GN (2005) VSV-tumor selective replication and protein translation. Oncogene 24:7710\u20137719","journal-title":"Oncogene"},{"key":"3_CR194","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270\u2013273","journal-title":"Nature"},{"key":"3_CR195","unstructured":"WHO (2022) WHO Coronavirus (COVID-19) dashboard. Available from: https:\/\/covid19.who.int\/. Accessed 5 Feb 2022"},{"key":"3_CR196","unstructured":"Paul-Ehrlich-Institut (2022) COVID-19 vaccines. Available from: https:\/\/www.pei.de\/EN\/medicinal-products\/vaccines-human\/covid-19\/covid-19-list-1.html;jsessionid=76487DF06F027705201F8D7E1BEA6908.intranet242. Accessed 6 Feb 2022"},{"key":"3_CR197","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026153118","volume":"118","author":"M Lu","year":"2021","unstructured":"Lu M, Dravid P, Zhang Y et al (2021) A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A 118:e2026153118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103810","volume":"75","author":"O Launay","year":"2022","unstructured":"Launay O, Artaud C, Lachatre M et al (2022) Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591\/TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. EBioMedicine 75:103810","journal-title":"EBioMedicine"},{"key":"3_CR199","volume":"iScience 24","author":"J Ohtsuka","year":"2021","unstructured":"Ohtsuka J, Imai M, Fukumura M et al (2021) Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. iScience 24:103379","journal-title":"Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2."},{"key":"3_CR200","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109744118","volume":"118","author":"X Liu","year":"2021","unstructured":"Liu X, Luongo C, Matsuoka Y et al (2021) A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. Proc Natl Acad Sci U S A 118:e2109744118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR201","doi-asserted-by":"publisher","first-page":"eabi5246","DOI":"10.1126\/sciadv.abi5246","volume":"7","author":"D An","year":"2021","unstructured":"An D, Li K, Rowe DK et al (2021) Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. Sci Adv 7:eabi5246","journal-title":"Sci Adv"},{"key":"3_CR202","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","volume":"11","author":"Y Yahalom-Ronen","year":"2020","unstructured":"Yahalom-Ronen Y, Tamir H, Melamed S et al (2020) A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 11:6402","journal-title":"Nat Commun"},{"issue":"465-474","key":"3_CR203","volume":"28","author":"JB Case","year":"2020","unstructured":"Case JB, Rothlauf PW, Chen RE et al (2020) Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe 28(465-474):e464","journal-title":"Cell Host Microbe"},{"key":"3_CR204","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41541-021-00352-1","volume":"6","author":"DC Malherbe","year":"2021","unstructured":"Malherbe DC, Kurup D, Wirblich C et al (2021) A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. NPJ Vaccines 6:91","journal-title":"NPJ Vaccines"},{"key":"3_CR205","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41541-020-00248-6","volume":"5","author":"D Kurup","year":"2020","unstructured":"Kurup D, Wirblich C, Ramage H et al (2020) Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines 5:98","journal-title":"NPJ Vaccines"},{"key":"3_CR206","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009383","volume":"17","author":"D Kurup","year":"2021","unstructured":"Kurup D, Malherbe DC, Wirblich C et al (2021) Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS Pathog 17:e1009383","journal-title":"PLoS Pathog"},{"key":"3_CR207","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh CL, Goldsmith JA, Schaub JM et al (2020) Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369:1501\u20131505","journal-title":"Science"},{"key":"3_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.792584","volume":"11","author":"LA Caldera-Crespo","year":"2022","unstructured":"Caldera-Crespo LA, Paidas MJ, Roy S et al (2022) Experimental models of COVID-19. Front Cell Infect Microbiol 11:792584","journal-title":"Front Cell Infect Microbiol"},{"key":"3_CR209","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/03079459995082","volume":"28","author":"O Werner","year":"1999","unstructured":"Werner O, R\u00f6mer-Oberd\u00f6rfer A, K\u00f6llner B et al (1999) Characterization of avian paramyxovirus type 1 strains isolated in Germany during 1992 to 1996. Avian Pathol 28:79\u201388","journal-title":"Avian Pathol"},{"key":"3_CR210","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1128\/JVI.01989-07","volume":"82","author":"Y Yan","year":"2008","unstructured":"Yan Y, Samal SK (2008) Role of intergenic sequences in newcastle disease virus RNA transcription and pathogenesis. J Virol 82:1323\u20131331","journal-title":"J Virol"},{"issue":"88-90","key":"3_CR211","first-page":"92","volume":"31","author":"M Geiser","year":"2001","unstructured":"Geiser M, Cebe R, Drewello D et al (2001) Integration of PCR fragments at any specific site within cloning vectors without the use of restriction enzymes and DNA ligase. Biotechniques 31(88-90):92","journal-title":"Biotechniques"},{"key":"3_CR212","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115318","volume":"9","author":"C Fu","year":"2014","unstructured":"Fu C, Donovan WP, Shikapwashya-Hasser O et al (2014) Hot Fusion: an efficient method to clone multiple DNA fragments as well as inverted repeats without ligase. PLoS One 9:e115318","journal-title":"PLoS One"}],"container-title":["Methods in Molecular Biology","RNA Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3770-8_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:51:11Z","timestamp":1717062671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3770-8_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9781071637692","9781071637708"],"references-count":212,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3770-8_3","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"31 May 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}